Atezolizumab (anti-PD-L1)

製品コード：A2004         Batch: A200411

印刷

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

製品説明

CAS No. 1380723-44-3
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 7.249mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

A2004-Atezolizumab-anti-PD-L1-1.gif

A2004-Atezolizumab-anti-PD-L1-2.gif

A2004-Atezolizumab-(anti-PD-L1).gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy [ Nat Commun, 2025, 16(1):4128] PubMed: 40319089
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC [ J Biomed Sci, 2025, 32(1):94] PubMed: 41068729
In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients [ Cell Death Dis, 2025, 16(1):286] PubMed: 40221409
Using extension-based mRNA display to design antibody-like proteinogenic peptides for human PD-L1 [ Protein Sci, 2025, 34(9):e70268] PubMed: 40852896
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) [ J Transl Med, 2025, 23(1):2] PubMed: 39748404
NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):132] PubMed: 40029463
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):143] PubMed: 40056167
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer [ iScience, 2025, 28(3):111943] PubMed: 40034862

人間や獣医の診断であるか治療的な使用のためにでない。